Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia in Complete Remission
|ClinicalTrials.gov Identifier: NCT00963521|
Recruitment Status : Completed
First Posted : August 21, 2009
Last Update Posted : May 13, 2011
RATIONALE: Vaccines made from dendritic cells may help the body build an effective immune response to kill cancer cells.
PURPOSE: This phase I trial is studying the side effects of vaccine therapy and to see how well it works in treating patients with acute myeloid leukemia in complete remission.
|Condition or disease||Intervention/treatment||Phase|
|Leukemia||Biological: therapeutic autologous dendritic cells||Phase 1|
- Assess the tolerability of autologous dendritic cell vaccine in patients with acute myelogenous leukemia in complete remission.
- Evaluate the emergence of an immune response.
- Determine the relapse rate.
- Assess the occurrence of residual disease.
OUTLINE: Patients receive increasing doses of blastic cells transformed in vitro by autologous dendritic cells (1/3 subcutaneously and 2/3 IV) every 3 weeks for up to 5 doses.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Official Title:||Pilot Study of Therapeutic Vaccination by Leukemic Blasts in Vitro Differentiated Dendritic Cells From Patients With Acute Myelogenous Leukemia in Complete Remission|
|Study Start Date :||June 2008|
|Actual Primary Completion Date :||May 2011|
- Adverse events at 6 months
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00963521
|Marseille Institute of Cancer - Institut J. Paoli and I. Calmettes|
|Marseille, France, 13273|
|OverallOfficial:||Christian Chabannon, MD, PhD||Institut Paoli-Calmettes|